The Health System and Population Health Implications of Large-Scale Diabetes Screening in India: A Microsimulation Model of Alternative Approaches

PLoS Medicine

Volumn 12, Issue 5, 2015, Pages

  Basu, Sanjay ^a,b   Millett, Christopher ^c,d   Vijan, Sandeep ^e,f   Hayward, Rodney A ^e,f   Kinra, Sanjay ^b   Ahuja, Rahoul ^a   Yudkin, John S ^g  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD GLUCOSE METER; COST BENEFIT ANALYSIS; DIABETES MELLITUS; FEMALE; HEALTH CARE; HEALTH SURVEY; HUMAN; INDIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR; SCREENING TEST; SENSITIVITY ANALYSIS; SIMULATION; WORLD HEALTH ORGANIZATION; AGED; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; ECONOMICS; MASS SCREENING; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PROCEDURES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; HUMANS; INDIA; MASS SCREENING; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84930536179     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001827     Document Type: Article

References (46)

1. Wild S, Roglic G, Green A, Sicree R, King H, (2004) Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047–1053. 15111519
2. Shaw JE, Sicree RA, Zimmet PZ, (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4–14. doi: 10.1016/j.diabres.2009.10.007 19896746
3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, et al. (2013) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095–2128.
4. International Diabetes Federation (2013) Diabetes atlas, 6th edition. Brussels: International Diabetes Federation.
5. Narayan KMV, Echouffo-Tcheugui JB, Mohan V, Ali MK, (2012) Global prevention and control of type 2 diabetes will require paradigm shifts in policies within and among countries. Health Aff (Millwood) 31: 84–92.
6. Chaturvedi V, Reddy KS, Prabhakaran D, Jeemon P, Ramakrishnan L, et al. (2008) Development of a clinical risk score in predicting undiagnosed diabetes in urban Asian Indian adults: a population-based study. CVD Prev Control 3: 141–151.
7. Ramachandran A, Snehalatha C, Vijay V, Wareham NJ, Colagiuri S, (2005) Derivation and validation of diabetes risk score for urban Asian Indians. Diabetes Res Clin Pract 70: 63–70. 16126124
8. Mohan V, Deepa R, Deepa M, Somannavar S, Datta M, (2005) A simplified Indian Diabetes Risk Score for screening for undiagnosed diabetic subjects. J Assoc Physicians India 53: 759–763. 16334618
9. Ministry of Health and Family Welfare (2014) National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke. Delhi: Government of India.
10. National Health Mission, Ministry of Health and Family Welfare (2013) Guidelines for the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke. Delhi: Government of India.
11. Wilson JMG, Jungner G, (1968) Principles and practice of screening for disease. Geneva: World Health Organization. http://apps.who.int/iris/bitstream/10665/37650/1/WHO_PHP_34.pdf?ua=1. Accessed 16 April 2015.
12. Ramachandran A, Snehalatha C, Dharmaraj D, Viswanathan M, (1992) Prevalence of glucose intolerance in Asian Indians: urban-rural difference and significance of upper body adiposity. Diabetes Care 15: 1348–1355. 1425100
13. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GEHM, et al. (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378: 156–167. doi: 10.1016/S0140-6736(11)60698-3 21705063
14. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, et al. (2012) Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 380: 1741–1748. doi: 10.1016/S0140-6736(12)61422-6 23040422
15. Ritchie GE, Kengne AP, Joshi R, Chow C, Neal B, et al. (2011) Comparison of near-patient capillary glucose measurement and a risk assessment questionnaire in screening for type 2 diabetes in a high-risk population in rural India. Diabetes Care 34: 44–49. doi: 10.2337/dc10-1270 21193620
16. Caro JJ, Briggs AH, Siebert U, Kuntz KM, (2012) Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1. Med Decis Making 32: 667–677. 22990082
17. United Nations (2013) World population prospects: the 2012 revision. Geneva: United Nations.
18. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR, et al. (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 101: 671–679. 11724655
19. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, et al. (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33: 1776–1781. 12105351
20. International Institute for Population Sciences (2008) National Family Health Survey, India 2005–06. Bombay: International Institute for Population Sciences.
21. American Diabetes Association (2014) Standards of medical care in diabetes—2014. Diabetes Care 37: S14–S80. doi: 10.2337/dc14-S014 24357209
22. World Health Organization (2011) Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Geneva: World Health Organization.
23. World Health Organization (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization.
24. Stanley TD, Doucouliagos H, (2012) Meta-regression analysis in economics and business [Internet]. New York: Routledge.
25. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378: 31–40. doi: 10.1016/S0140-6736(11)60679-X 21705069
26. Vellakkal S, Subramania SV, Millett C, Basu S, Stuckler D, et al. (2013) Socioeconomic inequalities in non-communicable diseases prevalence in India: disparities between self-reported diagnoses and standardized measures. PLoS ONE 8: e68219. doi: 10.1371/journal.pone.0068219 23869213
27. McKeigue PM, Shah B, Marmot MG, (1991) Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 337: 382–386. 1671422
28. McKeigue PM, Pierpoint T, Ferrie JE, Marmot MG, (1992) Relationship of glucose intolerance and hyperinsulinaemia to body fat pattern in south Asians and Europeans. Diabetologia 35: 785–791. 1511807
29. Forouhi NG, Jenkinson G, Thomas EL, Mullick S, Mierisova S, et al. (1999) Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. Diabetologia 42: 932–935. 10491752
30. Chiu M, Austin PC, Manuel DG, Shah BR, Tu JV, (2011) Deriving ethnic-specific BMI cutoff points for assessing diabetes risk. Diabetes Care 34: 1741–1748. doi: 10.2337/dc10-2300 21680722
31. Ntuk UE, Gill JMR, Mackay DF, Sattar N, Pell JP, (2014) Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK biobank participants. Diabetes Care 37: 2500–2507. doi: 10.2337/dc13-2966 24974975
32. World Health Organization (2014) Cost effectiveness and strategic planning (WHO-CHOICE). http://www.who.int/choice/cost-effectiveness/en/. Accessed 16 April 2015.
33. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM, (2013) UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 56: 1925–1933. doi: 10.1007/s00125-013-2940-y 23793713
34. Ghosh P, Kandhare AD, Raygude KS, Kumar VS, Rajmane AR, et al. (2012) Determination of the long term diabetes related complications and cardiovascular events using UKPDS risk engine and UKPDS outcomes model in a representative western Indian population. Asian Pac J Trop Dis 2 (Suppl 2): S642–S650.
35. Ebrahim S, Kinra S, Bowen L, Andersen E, Ben-Shlomo Y, et al. (2010) The effect of rural-to-urban migration on obesity and diabetes in India: a cross-sectional study. PLoS Med 7: e1000268. doi: 10.1371/journal.pmed.1000268 20436961
36. Knowler W, (2013) Impact of a lifestyle intervention on diabetes control and microvascular complications. 73rd Scientific Sessions; 21–25 Jun 2013; Chicago, Illinois, US.
37. Wing RR, Bolin P, Brancati FL, Bray GA, Look AHEAD Research Group, et al. (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369: 145–154. doi: 10.1056/NEJMoa1212914 23796131
38. Casagrande SS, Fradkin JE, Saydah SH, Rust KF, Cowie CC, (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 36: 2271–2279. doi: 10.2337/dc12-2258 23418368
39. World Health Organization (2012) Guidelines for primary health care in low-resource settings. Geneva: World Health Organization.
40. International Diabetes Federation (2012) Global guideline for type 2 diabetes. http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf. Accessed 16 April 2015.
41. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703–713. 9732337
42. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, et al. (2014) Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371: 1392–1406. doi: 10.1056/NEJMoa1407963 25234206
43. Vijan S, Sussman JB, Yudkin JS, Hayward RA, (2014) Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 174: 1227–1234. doi: 10.1001/jamainternmed.2014.2894 24979148
44. Sussman J, Vijan S, Hayward R, (2013) Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation 128: 2309–2317. doi: 10.1161/CIRCULATIONAHA.113.002290 24190955
45. Capewell S, (2008) Will screening individuals at high risk of cardiovascular events deliver large benefits? No. BMJ 337: a1395. doi: 10.1136/bmj.a1395 18755771
46. Narayan KMV, Chan J, Mohan V, (2011) Early identification of type 2 diabetes policy should be aligned with health systems strengthening. Diabetes Care 34: 244–246. doi: 10.2337/dc10-1952 21193623